Hearing loss is associated with higher levels of anxiety, interpersonal sensitivity, and hostility, as well as higher rates of dementia, especially in older adults who are also visually impaired.
Akili Interactive announced topline data from an open-label study (STARS-ADHD Adjunctive) of AKL-T01 for the treatment of attention deficit hyperactivity disorder in children with or without use of stimulants.
The researchers analyzed data from 1649 combat-exposed United States military veterans who were evaluated at a Veterans Affairs facility between 2009 and 2012 after deployment to the wars in Iraq and/or Afghanistan.
Autism spectrum disorder (ASD) is markedly heritable, with probandwise concordance of 96 percent, but there is variation in the severity of symptomatology above the diagnostic threshold.
Benzodiazepines are considered a third-line treatment for the management of anxiety and sleep disorders, after antidepressant medications and psychotherapy.
Researchers sought to identify the major leading nonpharmaceutical intervention for ADHD cognitive symptomology, as well as which cognitive symptoms are most amenable to change.
The key findings of the study, conducted in the world’s largest BD cohort with genotypic and phenotypic data, offer potential sleep-related genetic underpinnings for BD diagnostic groups.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
